TY - JOUR
T1 - Updates in the Diagnosis of Intraductal Neoplasms of the Pancreas
AU - Assarzadegan, Naziheh
AU - Babanianmansour, Sepideh
AU - Shi, Jiaqi
N1 - Funding Information:
JS is supported in part by the National Cancer Institute of the National Institutes of Health under award number K08CA234222.
Publisher Copyright:
Copyright © 2022 Assarzadegan, Babanianmansour and Shi.
PY - 2022/3/4
Y1 - 2022/3/4
N2 - Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer worldwide. There are many reasons for this dismal prognosis, including the advanced stage at the time of diagnosis and the lack of effective therapeutic approaches. Intraductal papillary mucinous neoplasms (IPMNs) represent detectable and treatable precursor lesions of PDAC. Our understanding of the pathology of IPMNs has evolved over the past few decades, and new advances in diagnostic tools have emerged. The new World Health Organization (WHO) classification scheme now recognizes the previously considered variants of IPMNs, such as intraductal oncocytic papillary neoplasms (IOPNs) and intraductal tubulopapillary neoplasms (ITPNs), as distinct neoplasms. New imaging and molecular diagnostic tests are being developed to recognize these PDAC precursor lesions better. Here, we review the advances in diagnostic tools for IPMNs, IOPNs, and ITPNs, emphasizing the new (5th edition, 2019) WHO classification for pathological diagnosis, molecular markers, new laboratory tests, and imaging tools.
AB - Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer worldwide. There are many reasons for this dismal prognosis, including the advanced stage at the time of diagnosis and the lack of effective therapeutic approaches. Intraductal papillary mucinous neoplasms (IPMNs) represent detectable and treatable precursor lesions of PDAC. Our understanding of the pathology of IPMNs has evolved over the past few decades, and new advances in diagnostic tools have emerged. The new World Health Organization (WHO) classification scheme now recognizes the previously considered variants of IPMNs, such as intraductal oncocytic papillary neoplasms (IOPNs) and intraductal tubulopapillary neoplasms (ITPNs), as distinct neoplasms. New imaging and molecular diagnostic tests are being developed to recognize these PDAC precursor lesions better. Here, we review the advances in diagnostic tools for IPMNs, IOPNs, and ITPNs, emphasizing the new (5th edition, 2019) WHO classification for pathological diagnosis, molecular markers, new laboratory tests, and imaging tools.
KW - classification
KW - intraductal oncocytic papillary neoplasm
KW - intraductal papillary mucinous neoplasm
KW - intraductal tubulopapillary neoplasm
KW - pancreatic ductal adenocarcinoma
UR - http://www.scopus.com/inward/record.url?scp=85127196291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127196291&partnerID=8YFLogxK
U2 - 10.3389/fphys.2022.856803
DO - 10.3389/fphys.2022.856803
M3 - Review article
C2 - 35309060
AN - SCOPUS:85127196291
SN - 1664-042X
VL - 13
JO - Frontiers in Physiology
JF - Frontiers in Physiology
M1 - 856803
ER -